Wednesday, July 8, 2026

biotech · Post Traumatic Stress Disorder · Prosthetic Joint Infection · ADPT

Adaptive Biotechnologies

Adaptive Biotechnologies is a biotech organization headquartered in Seattle, USA. It trades on NYSE under ticker ADPT. Primary therapeutic focus areas include Post Traumatic Stress Disorder, Prosthetic Joint Infection, O

1165 Eastlake Ave E, Seattle, Washington 98109, US HQ
2009 Founded
659 Employees
Public company Type
ADPT · NYSE Ticker
Company details
Status
Public
HQ
1165 Eastlake Ave E, Seattle, Washington 98109, US
Founded
2009
Employees
659
Programs
19
Drugs
23
Patents
12
Clinical program

Ceftriaxone

Phase 3 · small molecule · Community-acquired Pneumonia, Influenza, COVID-19

Ceftriaxone for Community-acquired Pneumonia, Influenza, COVID-19 is a Phase 3 program (small_molecule) at Adaptive Biotechnologies Corp with 1 ClinicalTrials.gov record(s).

Internal code U1111-1189-1653

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Adaptive Biotechnologies Corp
Phase
Phase 3
Modality
small_molecule
Indication
Community-acquired Pneumonia, Influenza, COVID-19
Status
active
Trials
1